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ABSTRACT
There is an urgent need for new tools for the rapid diagnosis of tuberculosis 
disease. We evaluated the potentials of 74 host markers as biomarkers for the 
immunological diagnosis of tuberculosis and monitoring of treatment response. Fifty-
five individuals that presented with signs and symptoms requiring investigation for 
tuberculosis disease were prospectively recruited prior to clinical diagnosis, at a 
health centre in Cape Town, South Africa. Patients were later classified as having 
tuberculosis disease or other respiratory diseases (ORD) using a combination 
of clinical, radiological and laboratory findings. Out of 74 host markers that were 
evaluated in plasma samples from study participants using a multiplex platform, 18 
showed potential as tuberculosis diagnostic candidates with the most promising being 
NCAM, CRP, SAP, IP-10, ferritin, TPA, I-309, and MIG, which diagnosed tuberculosis 
disease individually, with area under the ROC curve ≥0.80. Six-marker biosignatures 
containing NCAM diagnosed tuberculosis disease with a sensitivity of 100% (95%CI, 
86.3-100%) and specificity of 89.3% (95%CI, 67.6-97.3%) irrespective of HIV status, 
and 100% accuracy in the absence of HIV infection. Furthermore, the concentrations 
of 11 of these proteins changed with treatment, thereby indicating that they may be 
useful in monitoring of the response to tuberculosis treatment. Our findings have 
potential to be translated into a point-of-care screening test for tuberculosis, after 
future validation studies.
INTRODUCTION
Tuberculosis (TB) disease, although curable, still 
accounted for the deaths of 1.5 million people in 2014 
[1]. Rapid and accurate tools are urgently needed for early 
diagnosis of the disease, and monitoring of the response 
to treatment. The gold standard test for TB (culture) is not 
widely available, especially in resource-poor settings. The 
Ziehl Nielsen sputum smear test is often the only available 
diagnostic tool in these settings, even though its limitations 
are well publicised [2]. Month 2 culture conversion is the 
most investigated biomarker for TB treatment response, 
but the wide unavailability of culture and its long turn-
around time are serious limitations. Smear microscopy is 
not very useful for monitoring anti-TB treatment response 
as it is unable to distinguish live from dead bacilli [3]. The 
development of the geneXpert MTB/RIF test (Cepheid 
Inc., Sunnyvale, USA) was a significant advance in the 
TB diagnostic field as the test yields results within 2 hours, 
coupled with the detection of resistance to rifampicin, 
as a proxy for multi-drug resistant TB [4]. The high 
operating costs and need for infrastructure are amongst 
the major obstacles for its implementation in resource-
poor settings. The geneXpert test is also not useful in 
monitoring of TB treatment response as the test cannot 
distinguish between DNA from dead and live bacteria [5]. 
Immunodiagnostic techniques may be useful in both the 
diagnosis of TB disease and monitoring of the response 
to treatment, especially as they may be easily adaptable 
into rapid, point-of-care tests, which would be suitable in 
Oncotarget2www.impactjournals.com/oncotarget
resource-constrained settings. Furthermore, such tests will 
also be beneficial in cases where a conventional sputum-
based diagnosis (smear microscopy, culture or geneXpert) 
is difficult e.g. in paediatric TB and in individuals with 
extrapulmonary TB.
IFN-gamma (IFN-γ) release assays (IGRA) remain 
the most widely used commercial immunodiagnostic tests 
for TB. These assays have been shown to be useful in the 
diagnosis of infection with Mycobacterium tuberculosis 
(MTB) but as they cannot discriminate between active TB 
disease and latent MTB infection, they are of limited value 
in high TB-endemic areas. The use of IGRAs as tools for 
monitoring of the response to TB treatment has so far 
yielded conflicting results [6] [7]. An important limitation 
of overnight culture-based assays such as IGRAs is the 
fact that they are not suitable as point-of-care tests. These 
tests are therefore not ideal for resource-constrained 
settings. The potential value of diagnostic approaches 
that are based on the detection of host biomarkers ex 
vivo, in easily obtainable samples such as saliva, serum or 
plasma has been demonstrated in previous studies [8] [9] 
[10] [11]. Such host biomarker based tests in addition to 
being used as diagnostic tests for TB, may also be useful 
in monitoring of the response to TB treatment [8] [12] 
[13]. Despite the promise so far shown in these previous 
investigations, no validated diagnostic tests based on the 
detection of host biomarkers in unstimulated samples 
currently exist. It is therefore important to validate the 
potential biomarkers that have so far been identified, 
and also identify new candidate host markers that might 
be useful in conjunction with previously identified 
biosignatures, in the diagnosis of TB disease.
In the present study, we investigated multiple host 
markers, including previously identified promising host 
markers, and relatively new markers, some of which 
have not previously been investigated in the TB field, as 
candidates for the immunological diagnosis of TB disease 
and monitoring of the response to TB treatment. 
RESULTS
A total of 55 study participants, 22 of whom were 
culture positive TB patients were investigated in this 
study. The mean age of all study participants was 35.8 ± 
10.2 years and 14 (25%) were HIV infected. The clinical 
and demographic characteristics of study participants are 
shown in Table 1.
Utility of individual host markers in the diagnosis 
of TB disease
When the baseline concentrations of host markers 
in TB patients (n = 22) were compared to the levels 
detected in patients with ORD (n = 33), by the Mann 
Whitney U test, the concentrations of 23 out of the 74 
analytes were significantly different between the two 
groups. The median levels of CRP, SAP, PCT, ferritin, 
TPA, SAA, ADAMTS-13, p-selectin, GDF-15, I-309, 
IFN-γ, IP-10, TNF-α, CFH, MIG, ITAC, HCC-1 and 
MIP-4 were significantly higher in TB cases, whereas the 
levels of antithrombin III, Apo A-1, transthyretin, NCAM 
and BDNF were significantly higher in the ORD group. 
Trends (0.05 < p ≤ 0.01) towards higher levels of sFas, 
lipocalin-2, VEGF, PEDF, CC4 and IL-33 were observed 
in TB cases (Table 2). When the diagnostic accuracies of 
individual host markers were investigated by ROC curve 
analysis, the area under the ROC curve (AUC) was ≥ 0.70 
for 18 markers (Table 2). The most accurate single host 
markers included CRP, SAP, NCAM, TPA, I-309, and 
MIG, which all performed with AUC ≥ 0.80 (Table 2). 
Representative plots showing some of the most accurate 
individual host markers are shown in Figure 1. When 
data was stratified according to HIV infection status, 
concentrations of three additional markers (A2M, MIP-
1β and VEGF) became significant in the two groups, with 
AUC’s of 0.70, 0.69 and 0.69 respectively.
Table 1: Clinical and demographic characteristics of study participants. 
Number of participants All (n = 55)
TB 
(n = 22)
ORD
(n = 33)
Males, n (%) 22 (40) 7 (32) 15 (45)
Mean age,
(Years)±SD 35.8 ± 10.2 38.8 ±10.1 33.9 ± 9.9
HIV Infected, n(%) 14(25) 4(18) 10(30)
Quantiferon results
Positive, n (%) 34 (64) 15 (75) 19 (58)
Negative, n (%) 18 (34) 4 (20) 14 (42)
Indeterminate, n (%) 1 (2) 1 (5) 0 (0)
All the 22 TB patients included in the study were culture positive
Abbreviations: TB= pulmonary tuberculosis, SD=standard deviation
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Table 2: Median levels (and inter-quartile ranges in parenthesis) of host biomarkers detected in baseline plasma 
samples from pulmonary TB patients (n = 22) and individuals with other respiratory diseases (n = 33) and their 
diagnostic accuracies for TB disease.
Marker ORD(n = 33)
TB Disease
(n = 22) P value
AUC
(95% CI)
Cut-off value Sensitivity %
(95% CI)
Specificity %
(95% CI)
ADAMTS-13 3297(2569-4504) 4235(2766-8073) 0.044
0.66
(0.51- 0.81) > 3466 68 (45-86) 64 (45-80)
Antithrombin III 803100(624200-968800)
625700
(519000-714300) 0.01
0.70
(0.56- 0.84) <744162 91 (71-99) 61 (42-77)
Apo A-1 431400(334100-548700)
274300
(242800-351500) 0.0014
0.76
(0.62- 0.89) < 318930 73 (50-89) 82 (65-93)
BDNF 5774(3824-8838)
3791
(1683-6187) 0.017
0.69
(0.55-0.84) < 3467 45 (24-68) 91 (76-98)
CC4 114800(70110-176600)
151600
(95100-291100) 0.100
0.63
(0.48- 0.79) > 212263 32 (14-55) 97 (84-100)
CFH 729100(557000-795100)
875400
(715200-980300) 0.0072
0.72
(0.57- 0.86) > 808359 68 (45-86) 82 (65-93)
CRP 2019(440-6330)
52980
(10020-137400) P<0.0001
0.89
(0.79 -1.00) > 9081 82 (60-95) 90 (76-98)
Ferritin 62850(41840-120100)
161000
(116800-355300) P<0.0001
0.78
(0.64 - 0.92) > 93785 91 (71-99) 67 (48-82)
GDF-15 19.2(9.8-41.7) 49.24(25.10-125.5) 0.002
0.75
(0.62 - 0.88) > 21.06 91 (71-99) 55 (36-72)
HCC1 108000(73120-130200)
144100
(108500-171800) 0.0022
0.75
(0.61- 0.89) > 136956 59 (36-79) 85 (68-95)
I-309 1.24(1.1-1.4) 2.25(1.4-3.5) 0.0002
0.80
(0.67- 0.93) > 1.945 68 (45-86) 90 (73-98)
IFN-γ 5.78(0.39-49) 31.06(8.81-156) 0.02
0.69
(0.54 - 0.83) > 3.910 91 (70-99) 48 (31-66)
IL-33 88.77(21.75-211.5)
164.9
(70.79-251.9) 0.100
0.63
(0.48- 0.78) > 131.8 68 (45-86) 61 (42-77)
IP-10 444 (258-876) 1469(878-3865) P<0.0001
0.78
(0.64 - 0.91) > 746.6 86 (65-97) 73 (54-87)
ITAC 628.0(87.49-1253)
1106
(519.1-2042) 0.022
0.68
(0.54-0.83) > 276.5 95 (77-100) 36 (20-55)
Lipocalin-2 453.9 (300.5-567.3)
600.7
(346.7-1028) 0.062
0.65
(0.50- 0.80) > 552.8 59 (36-79) 76 (58-89)
MIG 312.4(87.21-1028)
3076
(592.2-13830) P<0.0001
0.81
(0.69- 0.94) > 1700 68 (45-86) 88 (72-97)
MIP-4 92.5(53.6-152)
208
(90-369) 0.012
0.70
(0.55- 0.85) > 220.9 50 (28-72) 91 (76-98)
NCAM 592100(430200-684200)
350800
(306800-421000) P<0.0001
0.88
(0.78- 0.98) < 477229 91 (71-99) 73 (54-87)
PCT 7520(6749-8370) 8702(8185-9888) 0.0009
0.77
(0.64- 0.90) > 8101 86 (65-97) 67 (48-82)
PEDF 10790(8852-12870)
12360
(10360-15270) 0.0502
0.66
(0.50- 0.81) > 11423 68 (45-86) 64 (45-80)
p-selectin 202(163-549) 441(263-796) 0.030
0.67
(0.53 - 0.82) > 265.7 77 (55-92) 58 (39-75)
SAA 5972(1324-12570) 9837(6078-43000) 0.0081
0.71 
(0.58 - 0.85) > 8626 68 (45-86) 70 (51-84)
SAP 21850(16980-24670)
30660
(23820-45050) P<0.0001
0.85
(0.72-0.98) > 25958 68 (45-86) 85 (68-95)
sFAS 5.3 (1.8-8.0)
8.03
(4.52-13.22) 0.065
0.65
(0.50- 0.81) >6.7 67 (43-85) 68 (49-83)
TNF-a 7.4(4.1-13.4) 15.9(11.8-24.6) 0.0024
0.74
(0.61- 0.88) > 10.85 82 (60-95) 73 (54-87)
TPA 5895(5187-6507) 7199 (6536-7702) 0.0002
0.80
(0.68- 0.92) > 6307 86 (65-97) 76 (58-89)
Transthyretin 544700(398000-638500)
293700
(212700-397500) 0.0005
0.78
(0.65- 0.91) < 416242 82 (60-95) 76 (58-89)
VEGF 147 (0-546)
289
(134.3-877) 0.081
0.64
(0.50- 0.79) > 175.6 73 (50-89) 55 (36-72)
Only analytes showing significant differences or trends between groups with the Mann-Whitney U test are shown. Optimal 
cut-off values and associated sensitivity and specificity were determined based on the Youden’s Index. The concentrations of 
CRP, SAP, SAA, antithrombin III, ADAMTS-13, p-selectin, GDF-15, Apo A-1, transthyretin, CFH, sFAS, lipocalin-2, MIP-4 
and CC4 are in ng/ml. The concentrations of all the other analytes are in pg/ml.
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Utility of multi-plasma marker biosignatures in 
the diagnosis of TB disease
When the data obtained from all the TB patients and 
those with ORD were fitted into General Discriminant 
Analysis (GDA) models regardless of HIV status, 
combinations between up to six different host markers 
showed potential in the diagnosis of TB disease. A five-
marker biosignature comprising of NCAM, SAP, ferritin, 
CFH and ECM-1 diagnosed TB disease with a sensitivity 
of 95.2% (95% CI, 81.0-99.9%) and specificity of 92.9% 
(95% CI, 70.8-98.9%) in the resubstitution classification 
matrix and sensitivity of 95.2% (95% CI, 81.0-99.9%) and 
specificity of 89.3% (95% CI, 66.4-97.2%) after leave-
one-out cross validation. However, the most optimal 
diagnostic biosignature irrespective of HIV status was 
a combination between six markers (NCAM, SAP, IL-
1β, sCD40L, IL-13 and Apo A-1), which diagnosed TB 
disease with a sensitivity 100% (95% CI, 86.3-100%) and 
specificity of 89.3% (95%CI, 67.6-97.3%) after leave-one-
out cross validation. The positive and negative predictive 
values of the six-marker biosignature were 87.5% 
(95% CI, 66.5-96.7%) and 100% (95%CI, 83.4-100%) 
respectively (Figure 2, Table 3).
When the GDA procedure was repeated after 
excluding the HIV infected individuals, two six-marker 
biosignatures:- NCAM, A2M, IL-22, ferritin, myoglobulin 
Figure 1: Concentrations of host markers detected in plasma samples from TB patients (n = 22) and individuals 
with other respiratory diseases (n = 33) and receiver operator characteristics curves showing the accuracies of these 
markers in the diagnosis of TB disease. Representative plots are shown for CRP, SAP, ferritin, IP-10, NCAM and MIG. Error bars 
in the scatter dot plots represent the median with interquartile range.
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and IL-12(p40), and NCAM, A2M, IL-22, ferritin, TNF-β 
and MIP-4, diagnosed TB disease with both sensitivity and 
specificity of 100% (AUC = 1.0, 95% CI, 1.0-1.0) (Table 
3). NCAM was the most frequent analyte in biosignatures, 
appearing in all the top 13 biosignatures for diagnosing 
TB disease regardless of HIV infection status, and in 
68%(23 of the 34) biosignatures that were generated for 
the diagnosis of TB disease after excluding HIV infected 
individuals. Other markers that occurred most frequently 
in diagnostic biosignatures for TB disease included GDF-
15, SAP, CFH, A2M, TNF-β, ferritin, SDF-1α amongst 
others (Figure 2).
Changes in host biomarker levels during the 
course of TB treatment
To investigate whether any of the 74 host markers 
could potentially be used to monitor the response to TB 
treatment, the host markers were evaluated in plasma 
samples that were collected from TB patients at the 
end of standard TB treatment (month 6). Of the 22 TB 
patients that were investigated in this study however, only 
15 (68%) returned to the clinic and provided samples at 
the end of treatment. Compared to baseline levels, the 
concentrations of 11 host markers changed significantly 
during the course of treatment. There was a significant 
decrease in the levels of CRP, SAP, ferritin, IFN-γ, VEGF, 
IP-10, CC3, CFH and α-1-antitrypsin from baseline to 
month 6, whereas a significant increase in the levels of 
transthyretin and MMP-2 was observed. The levels of IL-
1β, SAA, sFas and MIG showed trends towards decreasing 
levels from baseline to month 6, whereas Apo-CIII, Apo 
A-1 and GCP-2 showed trends towards increasing levels 
at the end of treatment (Figure 3).
DISCUSSION
We investigated the diagnostic potentials of 74 
host markers in plasma samples that were obtained from 
confirmed active TB cases and individuals with ORD, as 
candidates for the diagnosis of TB disease. Although 18 of 
the 74 host markers including relatively new biomarkers 
in the TB field namely; antithrombin III, GDF-15, NCAM, 
HCC1, MIP-4 and recently identified markers I-309, MIG, 
Apo A-1, transthyretin and CFH, showed potential in the 
diagnosis of TB disease, regardless of HIV infection status 
as determined by area under the ROC curve (AUC), the 
most optimal diagnostic biosignature irrespective of HIV 
infection status was a six-marker model comprising of 
NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo A-1, which 
diagnosed TB disease with a sensitivity of 100% and 
specificity of 89.3%, with promising positive and negative 
predictive values. In the absence of HIV infection, six-
marker biosignatures diagnosed TB disease with 100% 
accuracy. 
Amongst the 18 host markers that showed the most 
potential in the diagnosis of TB disease individually as 
determined by AUC, six (CRP, SAP, PCT, ferritin, TPA 
and SAA) were acute phase proteins, six (I-309, MIG, 
MIP-4, Apo A-1, transthyretin and CFH) were markers 
that play various roles in the body and have recently been 
identified as promising TB diagnostic candidates [16] 
[11], two (TNF-α and IP-10) are widely investigated TB 
biomarkers [17] whereas four (antithrombin III, GDF-15, 
NCAM, HCC1), were relatively new markers, which have 
not previously been investigated in the TB field. Other 
host markers including ECM-1, IL-1β, sCD40L and IL-13 
Table 3: Accuracies of plasma protein biosignatures in the diagnosis of TB disease.
Biosignature Resubstitution Classification matrix Leave-one-out cross validation
Sensitivity
%
(95% CI)
Specificity
%
(95%, CI)
PPV
%
(95% CI)
NPV
%
(95% CI)
Sensitivity
%
(95% CI)
Specificity
%
(95% CI)
PPV
%
(95% CI)
NPV
%
(95% CI)
Accuracy of biosignatures regardless of HIV infection status 
NCAM+ SAP+ ferritin+ 
CFH+ECM-1
95.2
(81.0-99.9)
92.9
(70.8-98.9)
90.9
(69.4-98.4)
96.3
(79.1-99.8)
95.2
(81-99.9)
89.3 
(66.4-97.2)
87
(65.3-96.6)
96.2
(78.4-99.8)
NCAM+ SAP+IL-
1β+sCD40L +IL-
13+Apo A-1
100
(86.3-100)
89.3
(67.6-97.3)
87.5
(66.5-96.7)
100
(83.4-100)
100
(86.3-100)
89.3
(67.6-97.3)
87.5
(66.5-96.7)
100
(83.4-100)
Accuracy of biosignatures in HIV uninfected individuals
NCAM+A2M+IL22+ 
ferritin+ 
myoglobulin+IL-12(p40)
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
NCAM+A2M+IL22+ 
ferritin+ TNF-β+MIP-4
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
100
(78.1-100)
100
(79.1-100)
Only the top two biosignatures generated for the diagnosis of TB disease, regardless of HIV infection status and in the HIV 
uninfected individuals only, are shown. The importance of the different analytes in biosignatures for the diagnosis of TB 
disease is shown in Figure 2.
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although not very promising individually in the current 
study, were included into the top diagnostic biosignatures 
for TB disease. 
 Acute phase proteins are primarily produced by 
the liver, and act as opsonins at inflammatory sites [18]. 
Serum CRP has been extensively studied and shown to 
be promising for both the diagnosis of TB disease and 
monitoring of TB treatment response [19] [20]. SAP, 
a homologue of CRP, has also been shown to have a 
protective role against bacterial infections [21]. Ferritin is 
a well-recognised protein in iron storage processes. It has 
long been established that iron acquisition is an essential 
virulence mechanism for pathogenic bacteria [22] [23]. 
The concentrations of all the acute phase proteins that 
showed potential in the current study were elevated in 
the TB patients, and this is in agreement with previous 
findings [23] [11] [24]. 
The chemokines; MIG(CXCL9), IP-10(CXCL10), 
ITAC(CXCL11) and I-309(CCL-1) are found in 
abundance in activated bronchial epithelium [25]. MIP-
4(CCL18) is a chemokine that is produced mainly by 
antigen presenting cells [26]. These chemokines play 
vital roles in the recruitment of activated T-cells to the 
site of infection [25] [27]. Our finding of significantly 
higher levels of these chemokines in the plasma of 
patients with active TB is in agreement with previous 
observations [16] [28] [29] [26]. The relatively new host 
markers investigated in the study (GDF-15, antithrombin 
III, HCC1 and NCAM) showed potential individually, 
in the diagnosis of TB disease. Other markers including 
Figure 2: Accuracy of multi-marker models in the diagnosis of TB disease. Receiver operator characteristics (ROC) curve 
showing the accuracy of the most accurate six-marker biosignature (NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo A-1) in the diagnosis of 
TB disease in all study participants, regardless of HIV infection status A., frequency of analytes in the top 13 general discriminant analysis 
(GDA) models that most accurately classified study participants as TB disease or ORD irrespective of HIV status B., ROC curve showing 
the accuracy of the most accurate six-marker biosignature (NCAM+A2M+IL-22+ferritin+ myoglobulin+IL-12(p40) or NCAM+A2M+IL-
22+ferritin+TNF-β+MIP-4) in the diagnosis of TB disease in HIV negative study participants C., and frequency of analytes in the top 34 
GDA models that most accurately classified study participants as TB disease or ORD in the absence of HIV infection D.. The bar graphs B. 
and D. indicate the frequency of analytes in the most accurate GDA models. 
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p-selectin, ADAMTS-13 and BDNF although not amongst 
the most promising single markers as demonstrated by 
ROC curve analysis, were significantly different between 
the TB patients and individuals with ORD, with the Mann-
Whitney U test. GDF-15 is a member of the transforming 
growth factor beta superfamily (TGF-β) and its expression 
is associated with tissue damage, but has also been 
reported to exhibit tissue protective functions [30] [31]. 
It has been identified as a prognostic marker for prostate 
cancer, with high serum levels observed in patients with 
liver cirrhosis and hepatocellular carcinoma [32] [33]. 
Antithrombin complexes are important mediators of 
the coagulation system, with antithrombin III being one 
of the most important inhibitors of this system [34]. 
Markedly lowered antithrombin III plasma levels have 
been observed in sepsis [35]. HCC1 has been identified 
as a monocyte chemoattractant, with high concentrations 
observed in patients with chronic renal failure [36]. 
P-selectin is part of the selectin family of cell adhesion 
molecules, that promotes inflammatory reactions [37]. 
ADAMTS-13 is a metalloprotease with thrombospondin 
repeats, and has shown low activity in patients with 
recurrent thrombaotic thrombocytopenic purpura [38] 
[39]. In a previous study by Liu et al, GDF-15 levels were 
not significantly different between TB patients, latently 
infected individuals and healthy controls [33]. However, 
GDF-15 levels showed potential in the current study. In 
agreement with the findings of the current study, Mukae 
et al observed significantly higher levels of p-selectin in 
TB patients in comparison to individuals with ORD [40]. 
For the other newly identified TB diagnostic candidates, 
we observed higher levels of HCC1 and ADAMTS-13 in 
TB patients, but the levels of antithrombin III and NCAM 
were higher in individuals with ORD. 
NCAM (CD56) is important in cell-cell or 
cell-matrix interactions, and is involved in neuronal 
differentiation, branching and survival [41]. It has been 
shown to play a role in lung tumor progression [42]. 
In the present study, we demonstrate for the first time, 
the potential of NCAM as a biomarker for TB disease. 
NCAM was the most frequently occurring marker in 
biosignatures for the diagnosis of TB disease, and was 
included in all the top 13 marker combinations for the 
diagnosis of TB disease regardless of HIV infection 
Figure 3: Before (baseline) and after treatment (month 6) concentrations of host markers in plasma samples from TB 
patients. Plasma was collected from patients at recruitment, prior to the initiation of anti-TB therapy and then at the end of standard TB 
treatment (month 6). Error bars indicate the Least Squared means with 95% Confidence Intervals.
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status, and in 68% of the models that were generated 
when HIV infected individuals were excluded. The 
combination of NCAM with five other markers (SAP, 
IL-1β, sCD40L, IL-13 and Apo A-1), diagnosed TB 
disease regardless of HIV infection status, with high 
accuracy, whereas all the TB patients and individuals with 
ORD were accurately classified (100% sensitivity and 
specificity) when NCAM was used in combination with 
either A2M+IL-22+ferritin+myoglobulin+IL-12(p40), or 
A2M+IL-22+ferritin+TNF-β+MIP-4, in the absence of 
HIV infection. In our previous serum-based study [11], 
optimal diagnosis of TB disease was achieved using a 
seven-marker biosignature of CRP, IFN-γ, IP-10, Apo A-1, 
transthyretin, SAA and CFH. While our previous study 
was conducted on 716 participants that were recruited 
from five different African countries, the current study 
was conducted on 55 individuals who were recruited at a 
single study site, and analysis was performed on plasma 
and not serum samples. There was excellent agreement 
between the findings of this and the serum study, as the 
diagnostic potential observed for individual host markers 
including CRP, SAA, SAP, CFH, Apo A-1, transthyretin, 
ferritin amongst others, was replicated in the current study. 
This implies that the new host markers identified in this 
study may be used in conjunction with, or as alternatives 
to the markers that were included in the previous seven-
marker biosignature [11] if a point-of-care screening 
test based on these biosignatures were to be developed. 
However, further studies are required to determine the best 
combination of analytes before such a screening test can 
be developed. 
In addition to being potentially useful as diagnostic 
candidates for TB disease, 11 of the markers investigated 
including CRP, SAP, ferritin, IP-10, α-1-antitrypsin 
changed with treatment, thereby indicating that they 
may be potential candidates for monitoring of the 
response to TB treatment. Although our observations 
for MMP-2 (increasing levels from baseline to month 
6) were contrary to the observations of Ugarte-Gil et al 
(decreasing levels from baseline to month 6 in sputum 
culture positive individuals after 2 weeks of treatment) 
[43], our observations for CRP, SAP, ferritin, IP-10, 
and α-1-antitrypsin are in agreement with findings from 
previous studies [44] [45]. More studies are required to 
validate the potential of these biomarkers, and investigate 
whether any of the markers would be able to distinguish 
between clinical cure, treatment failure and relapse. 
Furthermore, it will be important that samples collected 
early after the initiation of TB treatment and regularly in 
the course of treatment are included in such future studies, 
as biomarkers for early indication of the response to TB 
treatment are an urgent need worldwide. 
The main limitation of the current study was 
the small sample size. Inspite of this limitation, we 
confirmed the diagnostic potentials of host markers that 
were only recently identified as potential TB diagnostic 
candidates, identified new TB host biosignatures, and our 
study was done on individuals that presented with signs 
and symptoms, prior to the establishment of a clinical 
diagnosis, and at a community level health care clinic 
in a high-burden setting. Further studies are required to 
validate the new findings from our study preferably in 
larger numbers of study participants presenting with signs 
and symptoms requiring investigation for TB disease, and 
in studies conducted in other geographical regions. As the 
number of HIV infected study participants were limited in 
the current study, the biosignatures identified in this study 
require further investigation in HIV infected individuals. 
Importantly, HIV infected individuals included in such 
future studies should be staged with CD4 cell counts and 
viral loads so as to investigate the influence of severe 
HIV infection on the accuracy of the biosignatures. As 
we only investigated adult culture positive TB patients 
in the present study, the utility of the biosignatures also 
needs to be assessed in difficult to diagnose TB cases 
such as paediatric and extrapulmonary TB, smear and 
culture negative TB, and also in patients presenting with 
confirmed diseases that are similar to TB, including non-
TB pneumonias. Validated biosignatures could then be 
incorporated into a point-of-care screening test for TB, 
preferably based on the lateral flow technology as recently 
demonstrated in a multi-centered African study [46].
In conclusion have identified candidate host 
markers, some of which have not previously been 
investigated in TB, as diagnostic candidates for TB 
disease. The biosignatures identified in our study require 
further validation in large-scale multi-site prospective 
studies. 
MATERIALS AND METHODS
Study participants
Participants enrolled into the present study were 
individuals who presented with signs and symptoms 
requiring investigation for TB disease at the Fisantekraal 
Community Clinic in the outskirts of Cape Town, South 
Africa. The study was a sub-study of a larger diagnostic 
biomarker project (the African European Tuberculosis 
Consortium), that was ongoing at the study site and at field 
sites situated in six other African countries (www.ae-tbc.
eu). All study participants presented with persistent cough 
lasting ≥ 2 weeks and at least one of either fever, malaise, 
recent weight loss, night sweats, knowledge of close 
contact with a TB patient, haemoptysis, chest pain or loss 
of appetite. Participants were eligible for the study if they 
were 18 years or older and willing to give written informed 
consent for participation in the study, including consent for 
HIV testing. Patients were excluded if they were pregnant, 
had not been residing in the study community for more 
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than 3 months, were severely anaemic (haemoglobin < 
10 g/l), were on anti-TB treatment, had received anti-
TB treatment in the previous 90 days or if they were on 
quinolone or aminoglycoside antibiotics during the past 
60 days. The study was approved by the Health Research 
Ethics Committee of the Faculty of Medicine and Health 
Sciences of the University of Stellenbosch.
Sample collection and diagnostic tests
At enrolment, 6ml of blood was collected into 
heparinized BD vacutainer tubes (BD Biosciences, 
Franklin Lakes, NJ, USA) and transported to the 
laboratory at 4-8OC for further processing. Upon receipt 
in the laboratory, tubes were centrifuged at 2000 rpm for 
10 minutes after which plasma was harvested, aliquoted 
and stored at -80 OC until analysed. Sputum samples were 
collected from all study participants and cultured using the 
MGIT method (BD Biosciences). Positive MGIT cultures 
were examined for acid fast bacilli using the Ziehl-Neelsen 
technique (to check for contamination), followed by 
Capilia TB testing (TAUNS, Numazu, Japan), to confirm 
the isolation of organisms of the M.TB complex, before 
being designated as positive cultures. 
Classification of study participants and reference 
standard
As previously described, participants were classified 
as definite TB cases, probable TB cases, participants with 
other respiratory diseases (ORD) or questionable disease 
status using a combination of clinical, radiological, and 
laboratory findings [8]. However, only definite TB cases 
(culture positive individuals) and those with ORD were 
included in this discovery study. Briefly, individuals with 
ORD had a range of other diagnoses, including upper 
and lower respiratory tract infections (viral and bacterial 
infections, although attempts to identify organisms by 
bacterial or viral cultures were not made), and acute 
exacerbations of chronic obstructive pulmonary disease 
or asthma. Because of the disproportionately high number 
of individuals with ORD, we included all the 22 culture 
positive TB cases that were available at the study site 
and randomly selected 33 individuals with ORD from the 
study biobank, for inclusion into the current study. 
Luminex multiplex immunoassay
The concentrations of 74 host markers including 
alpha-2-macroglobulin (A2M) , haptoglobin, C-reactive 
protein (CRP), serum amyloid P (SAP), procalcitonin 
(PCT), ferritin, tissue plasminogen activator (TPA), 
fibrinogen, serum amyloid A (SAA) (kits purchased 
from Bio-Rad Laboratories, Hercules, CA, USA), 
vitronectin, extracellular matrix protein 1 (ECM1), 
antithrombin III, vitamin D binding protein (VDBP), 
sFas, granzyme A, sFasL, sCD137, granzyme B, perforin, 
myoglobulin, ADAMTS13, P-selectin, lipocalin-2, 
growth differentiation factor (GDF) -15 , thrombopoietin 
(TPO), stem cell factor (SCF), B-cell attracting 
chemokine (BCA)-1, epithelial neutrophil activating 
protein (ENA-78), thymic stromal lymphopoietin 
(TSLP), I-309(CCL-1), stromal cell derived factor-1 
alpha (SDF-1α), IFN-γ, IFN-α2, interferon gamma 
inducible protein (IP)-10 (CXCL10), macrophage 
inflammatory protein (MIP)-1β, tumor necrosis factor 
(TNF)-α, TNF-β, vascular endothelial growth factor 
(VEGF), soluble CD40 ligand (sCD40L), apolipoprotein 
(Apo) A-1, Apo CIII, complement component 3 (CC3), 
transthyretin, complement factor H (CFH), total 
plasminogen activator inhibitor-1 (PAI-1), neural cell 
adhesion molecule (NCAM), brain-derived neurotrophic 
factor (BDNF), cathepsin D, myeloperoxidase (MPO), 
matrix metalloproteinase (MMP)-2, MMP-9, monokine 
induced by gamma interferon (MIG/CXCL9), granulocyte 
chemotactic protein-2 (GCP2), interferon inducible T-cell 
alpha chemoattractant (I-TAC/CXCL11), hemofiltrate CC 
chemokine-1 (HCC1), α1-antitrypsin, pigment epithelium 
derived factor (PEDF), macrophage inflammatory 
protein-4 (MIP-4/CCL18), complement C4, interleukin 
(IL)-17F, IL-17A, IL-22, IL-33, IL-21, IL-23, IL-25, IL-
31, IL-28A, IL-16, IL-1β, IL-12(p40), IL-13, IL-11 and 
IL-29 (kits purchased from Merck Millipore, Billerica, 
MA, USA), were investigated in plasma samples 
from all the study participants. The experiments were 
performed blindly, according to the instructions of the 
kit manufacturers, on the Bio-Plex platform (Bio-Rad). 
The Bio-Plex manager Software version 6.1 was used 
for bead acquisition and analysis of median fluorescence 
intensities.
Statistical analysis
Differences in the concentrations of host markers 
between TB patients and individuals with ORD were 
analysed using the Mann-Whitney U test. The diagnostic 
abilities of individual host markers were assessed by 
receiver operator characteristics (ROC) curve analysis. 
Optimal cut-off values and associated sensitivity and 
specificity were determined based on the Youden’s 
Index [14]. The predictive abilities of combinations of 
host markers were investigated by general discriminant 
analysis (GDA), with leave-one-out cross validation [15]. 
Differences in the expression profiles of host markers 
during the course of TB treatment were analysed using 
mixed model repeated measures analysis of variance 
(ANOVA), with Fisher’s Least Significant Difference 
(LSD) post hoc testing. P-values ≤ 0.05 were considered 
significant. The data were analysed using Statistica 
(Statsoft, Ohio, USA) and Graphpad Prism version 5 
Oncotarget10www.impactjournals.com/oncotarget
(Graphpad Software Inc., CA, USA). 
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